We have studied the effects of positive expiratory pressure (PEP), continuous positive airway pressure (CPAP) and hyperventilation on 9 hypoxemic and hypercapnic chronic obstructive pulmonary disease (COPD) patients. All the patients were in a stable condition and received continuous oxygen. PEP and nasal CPAP were each given for 3 days in random order once every hour during the day and 3 times overnight. The effects of treatment were compared with a 3-day period in which the patients had no treatment for CO2 elimination. The effects were based on transcutaneous measurements of PO2 (PtcO2), PCO2 (PtcCO2) and SO2 (SpO2) and arterial blood gas measurements. The transcutaneous measurements showed that the PEP treatment reduced the PtcCO2 in COPD patients by 0.5 kPa and the CPAP treatment reduced it by 0.1 kPa (p < 0.05). The hyperventilation maneuver caused a decrease in the PtcCO2 of 0.7 kPa. The nocturnal treatments and measurements were all similar to the daytime measurements; the PtcCO2 decreased by 0.6 kPa using PEP and by 0.3 kPa using CPAP (p < 0.01). This indicated that all 3 methods reduced the PtcCO2, but only in the short term as the effects lasted for less than 4 min. COPD patients had no "late response" after any form of treatment. Arterial blood gases in COPD patients showed an elevation in PaCO2 (1.2 kPa) and a decrease in PaO2 and SaO2 during the night (11 pm to 7 am) without treatment. After 3 days of treatment with PEP and CPAP, the same pattern was noticed. The PaCO2 increased with both therapies, 1.3 kPa with PEP and 0.6 kPa with CPAP. Our data indicate that the effects were not of clinical significance and there is no justification for treating stable hypercapnic COPD patients with these methods.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.